| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8714131 | The Journal of Allergy and Clinical Immunology: In Practice | 2018 | 5 Pages |
Abstract
Looking at this selected population, we suggest that mastocytosis should be considered in patients developing severe reactions at re-sting after VIT discontinuation and, as a speculation, patients with mastocytosis and HVA should be VIT-treated lifelong.
Keywords
Related Topics
Life Sciences
Immunology and Microbiology
Immunology
Authors
Patrizia MD, Roberta MD, Mauro MD, Massimiliano MD, Luigi MD, Elisa MD, Maurizio MD, Federico MD, Maria Teresa MD, Chiara MD, Marina MD, Elisa MD, Fabio Lodi MD, Maria Beatrice MD, Anna Rosaria MD, Giovanni MD,